Full Press Release Details
IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP Deletion Urothelial and Lung Cancer as Late Breaker Oral Presentation at EORTC NCI AACR 2024.
IDYA
IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP Deletion Urothelial and Lung Cancer as Late Breaker Oral Presentation at EORTC NCI AACR 2024
Key Takeaway: IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP Deletion Urothelial and Lung Cancer as Late Breaker Oral Presentation at EORTC NCI AACR 2024
Price reaction · baseline $29.2 (2024-10-24 close) · hit after-hours · 2 other IDYA headline(s) in the window, move may be shared
day 0 close · peak
+0.3%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma